Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically
superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed
dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to
demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the
last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active
study medication at the end of a 6 to 8-week treatment period.